ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
- Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
- ViaNautis’s polyNaut® platform applies advanced polymer materials and in silico screening to precisely guide genetic molecules such as pDNA, mRNA, siRNA and ASOs to their intended targets.
- ViaNautis presents an excellent opportunity in the world of genetic therapies by enabling the delivery of cargoes to otherwise inaccessible sites of action in the body.
- It opens a plethora of novel prospects in the world of genetic therapies, offering the ability to reach previously inaccessible treatment sites.